article thumbnail

Uber Health Launches Grocery, Over-the-counter Delivery Service for Patients

MedCity News

Providers and payers will be able to use Uber Health to deliver healthy groceries and over-the-counter items to patients who need them. They’ll be able to do this on the same platform they use to request non-emergency medical transportation and prescription delivery.

article thumbnail

Uber Health, Socially Determined Strike Partnership

MedCity News

Through a new partnership, payers and providers will be able to leverage Socially Determined’s social risk data to identify which patients have barriers to accessing healthcare and what those barriers are.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The financial toxicity of treating cancer

World of DTC Marketing

(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. transportation), and indirect expenses (e.g., Patients who experience financial hardship during cancer treatment are at higher risk for treatment nonadherence, poor quality of life, and worse survival. population.

Insurance 273
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.

article thumbnail

Ipsen concludes purchase of Albireo Pharma

Pharmaceutical Technology

Albireo’s pipeline includes its lead asset, Bylvay (odevixibat), a potent, once-a-day, oral, non-systemic, ileal bile acid transport inhibitor (IBATi). In 2021, it secured regulatory approvals in the US to treat pruritus in progressive familial intrahepatic cholestasis (PFIC) in patients aged three months and above.

Pharma 52
article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS). More than 90% of patients who received treatment with odevixibat were pruritus responders.

article thumbnail

Embedding the Patient Point of View in Everything You Do

PM360

The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?